Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$8.40 USD

8.40
310,518

-0.27 (-3.11%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $8.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

PacBio's (PACB) New Solution to Boost Public Health Protection

by Zacks Equity Research

PacBio's (PACB) newly launched end-to-end solution is likely to help in the fight against infectious diseases and bolster public health response to pathogen threats.

Zacks Equity Research

Veeva Systems (VEEV) Vault Quality Suite Gets Adopted by CBM

by Zacks Equity Research

Veeva Systems' (VEEV) product gets adopted by CBM. This can drive the development and delivery of groundbreaking treatments for patients.

Zacks Equity Research

Baxter's (BAX) $100M Investment to Strengthen Global Presence

by Zacks Equity Research

Baxter's (BAX) strategic investment to help expand the manufacturing footprint of BPS and ensure improvement in products.

Zacks Equity Research

Here's Why You Should Invest in West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.

Zacks Equity Research

Cooper Companies' (COO) Buyout to Boost Women's Healthcare

by Zacks Equity Research

Cooper Companies' (COO) agrees to acquire Generate Life Sciences. It will be an important addition to the former's present offerings, while improving women's healthcare.

Zacks Equity Research

Surmodics (SRDX) Stock Loses 2.2% Despite Q4 Earnings Beat

by Zacks Equity Research

Surmodics' (SRDX) fiscal fourth-quarter results reflect benefits from segmental strength.

Zacks Equity Research

Shockwave Medical (SWAV) Gains 0.6% Post Q3 Earnings Beat

by Zacks Equity Research

Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.

Zacks Equity Research

Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Inari Medical's (NARI) third-quarter results benefit from new product launches and continued U.S. commercial expansion.

Zacks Equity Research

Cardinal Health (CAH) Q1 Earnings Lag, Revenues Top Estimates

by Zacks Equity Research

Although Cardinal Health (CAH) witnessed gross margin contraction in its fiscal first-quarter results, rise in revenues in both its segments is encouraging.

Zacks Equity Research

AMN Healthcare (AMN) Loses 13.1% Despite Q3 Earnings Beat

by Zacks Equity Research

AMN Healthcare's (AMN) robust Q3 results demonstrate its segmental strength.

Zacks Equity Research

Glaukos (GKOS) Gains 3.6% Despite Reporting a Loss in Q3

by Zacks Equity Research

Despite reporting third-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.

Zacks Equity Research

LHC Group (LHCG) Q3 Earnings Match Estimates, Down Y/Y

by Zacks Equity Research

LHC Group's (LHCG) third-quarter results benefit from organic growth in both home health and hospice admissions.

Zacks Equity Research

Inogen (INGN) Earnings and Revenues Surpass Estimates in Q3

by Zacks Equity Research

Inogen's (INGN) third-quarter results benefit from higher revenues across its segments.

Zacks Equity Research

AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal fourth-quarter results benefit from segmental growth.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) third-quarter results benefit from strong segmental performance.

Zacks Equity Research

Change Healthcare (CHNG) Q2 Earnings Beat, Revenues Miss

by Zacks Equity Research

Change Healthcare's (CHNG) fiscal second-quarter results benefit from solid performance across Software and Analytics and Network Solutions segments.

Zacks Equity Research

Fresenius Medical (FMS) Q3 Earnings Beat Estimates, Down Y/Y

by Zacks Equity Research

Fresenius Medical's (FMS) third-quarter earnings benefit from strong performance across the regions, Asia Pacific and Latin America.

Zacks Equity Research

PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) third-quarter results benefit from strong segmental performance.

Zacks Equity Research

Catalent (CTLT) Q1 Earnings Top Estimates, FY22 View Up

by Zacks Equity Research

Catalent's (CTLT) robust performance across most of its segments drives its first-quarter fiscal 2022 top line.

Zacks Equity Research

McKesson (MCK) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

McKesson's (MCK) fiscal second-quarter 2022 results benefit from substantial growth in the Medical-Surgical Solutions business.

Zacks Equity Research

NextGen Healthcare (NXGN) Gains 9.7% Since Q2 Earnings Beat

by Zacks Equity Research

NextGen Healthcare's (NXGN) fiscal second-quarter earnings reflect strong segmental performance.

Zacks Equity Research

OPKO Health's (OPK) Q3 Earnings, Revenues Top Estimates

by Zacks Equity Research

OPKO Health's (OPK) third-quarter results benefit from strength in its Pharmaceuticals segment, backed by robust RAYALDEE sales.

Zacks Equity Research

Integer Holdings (ITGR) Beats on Q3 Earnings, Ups 2021 EPS View

by Zacks Equity Research

Integer Holdings' (ITGR) third-quarter results reflect robust segmental performances along with strength in the majority of the product lines.

Zacks Equity Research

Merit Medical's (MMSI) Q3 Earnings, Revenues Top Estimates

by Zacks Equity Research

Merit Medical (MMSI), in the third quarter, benefits from revenue growth in its Cardiovascular segment, and from the majority of the product categories within its Cardiovascular unit.

Zacks Equity Research

Cerner (CERN) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Cerner's (CERN) third-quarter results benefit from gains across four of its business units.